Liquidia Shares Plunge Following Adverse Patent Ruling in United Therapeutics Dispute

Key Facts

1Liquidia shares dropped significantly following a court ruling in a patent dispute with United Therapeutics.

Liquidia Corporation shares dropped significantly following a court ruling in a patent dispute with United Therapeutics. Seeking Alpha reported that Judge Richard G. Andrews denied Liquidia's motion to strike, a decision that weighed heavily on the company's market valuation.

LQDA closed at $70.69 on September 29, 2026, while United Therapeutics (UTHR) closed at $481.47 on the same date. The legal setback is viewed as a challenge to Liquidia's competitive position and its product pipeline relative to its rival.